Mesangial Cell Mammalian Target of Rapamycin Complex 1 Activation Results in Mesangial Expansion

Area of Science:

• Nephrology
• Molecular Biology
• Pathology

Background:

• Glomerular diseases often involve mesangial expansion and proliferation, leading to glomerulosclerosis.
• The molecular pathways driving these pathological changes in mesangial cells are not fully understood.
• The mammalian target of rapamycin complex 1 (mTORC1) pathway is a key regulator of cell growth and metabolism.

Purpose of the Study:

• To investigate the role of the mTORC1-S6 kinase pathway in mesangial expansion and proliferation.
• To determine if inhibiting mTORC1 can ameliorate pathological changes in the glomerulus.
• To assess the clinical relevance of mesangial cell mTORC1 activation in human glomerular diseases.

Main Methods:

• Utilized tamoxifen-induced Foxd1-Cre mice with tuberous sclerosis complex 1 (TSC1) ablation to specifically target the mTORC1 pathway in mesangial cells.
• Administered rapamycin, an mTORC1 inhibitor, to assess its therapeutic effect on mesangial expansion.
• Analyzed biopsy specimens from patients with IgA nephropathy, lupus nephritis, and diabetic nephropathy for markers of mTORC1 activation.

Main Results:

• Ablation of TSC1 in mice led to significant mesangial expansion with increased collagen production but no significant mesangial proliferation or albuminuria.
• Rapamycin treatment effectively suppressed mesangial expansion in the mouse model.
• Mesangial cell mTORC1 activation was observed in human IgA nephropathy and lupus mesangial proliferative nephritis, but not in early diabetic nephropathy.

Conclusions:

• Mesangial cell mTORC1 activation is a key driver of mesangial expansion in glomerular diseases.
• Targeting the mTORC1 pathway holds potential for treating human glomerular diseases characterized by mesangial expansion.
• The study validates the use of tamoxifen-inducible mesangial-specific Cre-loxP systems for studying glomerular diseases in adult models.